Learn about the innovative method to create aptamers that could revolutionise treatments for infectious diseases.

Explore the potential of protein design with the new deep learning approach from Chongqing University to enhance binding ...

While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is ...

Learn how radiopharmaceuticals are transforming nuclear medicine and cancer therapy through targeted diagnostics and ...

Explore the collaboration between lab and data scientists to overcome communication challenges in life sciences.

Forget the buzzwords – SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems. This year, the focus wasn’t on bold ...

A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.

The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation. Housed within the ...

The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.

The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.

The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.